ENDOCYTE INC's ticker is ECYT and the CUSIP is 29269A102. A total of 98 filers reported holding ENDOCYTE INC in Q1 2015. The put-call ratio across all filers is 2.19 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $1,589,000 | +25.9% | 174,800 | -40.7% | 0.02% | +21.4% |
| Q4 2017 | $1,262,000 | +167.4% | 294,800 | -11.9% | 0.01% | +180.0% |
| Q3 2017 | $472,000 | -6.0% | 334,800 | 0.0% | 0.01% | -16.7% |
| Q2 2017 | $502,000 | -0.2% | 334,800 | +71.0% | 0.01% | 0.0% |
| Q1 2017 | $503,000 | +0.8% | 195,800 | 0.0% | 0.01% | -14.3% |
| Q4 2016 | $499,000 | -17.5% | 195,800 | 0.0% | 0.01% | -22.2% |
| Q3 2016 | $605,000 | -3.8% | 195,800 | 0.0% | 0.01% | -10.0% |
| Q2 2016 | $629,000 | +16.1% | 195,800 | +11.9% | 0.01% | +11.1% |
| Q1 2016 | $542,000 | -22.7% | 174,900 | 0.0% | 0.01% | -30.8% |
| Q4 2015 | $701,000 | -12.5% | 174,900 | 0.0% | 0.01% | -23.5% |
| Q3 2015 | $801,000 | -11.8% | 174,900 | 0.0% | 0.02% | -5.6% |
| Q2 2015 | $908,000 | +16.1% | 174,900 | +40.0% | 0.02% | +12.5% |
| Q1 2015 | $782,000 | -0.5% | 124,900 | 0.0% | 0.02% | -11.1% |
| Q4 2014 | $786,000 | – | 124,900 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 4,300,000 | $59,340,000 | 17.76% |
| RA Capital Management | 5,649,884 | $77,968,000 | 5.06% |
| Avoro Capital Advisors LLC | 5,695,200 | $78,594,000 | 3.03% |
| Crosspoint Capital Strategies, LLC | 107,620 | $1,485,000 | 2.84% |
| Ghost Tree Capital, LLC | 500,000 | $6,900,000 | 2.03% |
| EMORY UNIVERSITY | 205,295 | $2,833,000 | 1.88% |
| Asymmetry Capital Management, L.P. | 103,159 | $1,424,000 | 1.40% |
| NEXTHERA CAPITAL LP | 596,000 | $8,225,000 | 1.27% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,324,299 | $32,075,000 | 1.13% |
| PFM Health Sciences, LP | 4,068,608 | $56,147,000 | 0.88% |